Treatment of hormone dependent advanced prostate cancer.
Dosage/Direction for Use
Administer as a single SC inj. 22.5 mg inj Every 3 mth. 45 mg inj Every 6 mth.
Contraindications
Hypersensitivity to leuprorelin acetate or to other GnRH agonists.
Special Precautions
Transient increase in serum conc of testosterone, dihydrotestosterone & acid phosphatase during the 1st wk of treatment. Institute standard treatment if spinal cord compression or renal impairment develops. Closely monitor patients w/ vertebral &/or brain metastases as well as w/ urinary tract obstruction. Decreased bone density in men who had orchiectomy. May impair ability to drive or operate machinery. Pregnancy & lactation.
Adverse Reactions
Hot flushes; ecchymoses, erythema; fatigue, inj site burning & paresthesia.
Sign Out
